Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
about the author
Sarah Cohen
Contributor
sar_cohen@hotmail.com
author articles
Bayer's research and development teams settle into new, $140M Kendall Square digs
3 years ago
R&D
Pharma
#BIO22: The bear market may be mauling biotech stocks, but the fundamentals still look good to real estate developers
3 years ago
Financing
Deals
#BIO22: Are biotech buyouts finally coming into vogue? Here's what to look for in H2 M&A
3 years ago
Financing
Deals